LANSING, MI — (Marketwire) — 09/07/10 — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that scientists working in collaboration with the Company have successfully created transgenic silkworms. The silkworms were successfully genetically engineered with targeted spider silk DNA sequences.

“We are very excited to be able to announce our genetic engineering success,” said CEO Kim K. Thompson. “The creation of these transgenics was greeted with much celebration among the scientists and in the corporate office. In my view our accomplishment establishes that we have been on the right track all along. This achievement is a landmark event for the Company. It clears a major hurdle in our path and puts us well ahead of our development schedule.”

In addition to the news released today, the Company plans to hold a press conference to discuss other significant laboratory developments. That conference is expected to take place later this month.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:
Kraig Biocraft Laboratories, Inc.
Kim K. Thompson
CEO
(517) 336-0807

LANSING, Mich., August 24, 2010 –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, is sending out an advance press advisory today describing the Company’s plan to hold a press conference for the purpose of announcing laboratory developments. The press conference is tentatively scheduled for mid to late September.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

Kraig Biocraft Laboratories, Inc.
120 North Washington Square, Suite 805
Lansing , Michigan 48933

August 24, 2010

Dear Shareholder,

Kraig Biocraft Laboratories has made great strides in the last several months, and I believe that we, as a company, are gaining significant momentum both in the laboratory and in terms of corporate developments.

On the corporate side, one of the most difficult challenges and hurdles faced by the Company was navigating the credit crunch and meltdown of the US and European financial sectors in 2008 and its aftermath. Many advanced biotechnology companies collapsed and permanently closed their doors as their sources of finance dried up. I was personally saddened to see the biotechnology industry decimated by the financial meltdown that it had no part in creating.

I was determined that Kraig would not suffer the fate of others in our industry just at the time when we believed that we were on the verge of remarkable progress. We took immediate action and implemented a strategy which combined streamlining our already lean operations, a ten for one forward stock split and an S1 Securities registration. It has taken more than a year for that plan to play out, but in late June we were able to announce that our S1 had been declared effective.

What enabled Kraig to survive the financial meltdown when larger biotechnology companies all around us were collapsing was a combination of our innovative business strategy and our perseverance based on the knowledge of the importance and viability of our work. As a vital and essential part of our corporate community we want to thank you our shareholders for your vision and fortitude. We have now ridden together through some of the toughest times in our nation’s financial history.

Even before our S1 registration was declared effective, we had the confidence in our business model to negotiate a new collaborative research and development agreement with the University of Notre Dame. This agreement replaces our prior agreement with the university and places Kraig on sound footing for further scientific developments in 2010 and 2011. A word of acknowledgement for the work and vision of the university researchers and administrators is in order here.

Of course, while all this has been going on, and while the stock markets have fallen and partially risen, scientists, researchers and genetic engineers have continued to work for the creation and material development of the Company’s vision for high performance polymers including most notably recombinant spider silk.

This morning the Company issued a press conference advisory. Kraig plans to hold a press conference for the purpose of announcing laboratory developments. I have tentatively scheduled the conference for mid to late September. This is a very exciting time for the Company.

While we as a company are greatly looking forward to September, I do believe that our future over the next twelve months will be even brighter. We appear to be gaining momentum in the laboratory, and we believe that in the coming months we will be able to build on the foundations that have been laid by our researchers over the last year.

Thank you again for sticking with us when promising technology companies all around us were collapsing. I do believe that the coming months of 2010 and most especially the coming year of 2011 will be the best and brightest for Kraig Biocraft Laboratories.

Kim Thompson, CEO

Forward-looking statements:

This document includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

LANSING, MI, Aug 05, 2010 (MARKETWIRE via COMTEX) — KraigBiocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers including spider silk, today confirmed that earlier this year the Company entered into a new collaborative research and development agreement with the University of Notre Dame relating to the development of new polymers.

“The rate of progress and scientific development achieved over the last twelve months has exceeded our expectations. I believe that we are now ahead of our scheduled timeline for R&D and product development,” said Kim Thompson, Kraig CEO. “The new collaborative research agreement was designed to help us maintain that momentum. We are also hopeful that our recently completed S1 registration will enable the Company to further accelerate our development of new materials.”

For more information on KraigBiocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.

Kim K. Thompson CEO

LANSING, Mich., Jun 22, 2010 (BUSINESS WIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB ), a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.

“After working on this for nearly nine months, we are very happy to announce that the SEC has informed the Company that its S1 registration is now effective,” said CEO Kim K. Thompson. “The S1 registration lays the foundation for our financing program over the next twenty four months. When we originally filed the S1 our legal advisors told us that we could expect a delay of at least forty five days. Those forty five days ultimately turned into almost nine months. While we have been pursuing this clearance our legal advisors informed us that the Company should limit its public communication to avoid the perception of any promotion. We want to thank all of our shareholders for their patience during this arduous process and we look forward to what we now believe will be a very successful year for Kraig Biocraft Laboratories.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories please visit the Company’s web site: www.KraigLabs.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. is applying its proprietary genetic engineering technology to find solutions in the areas of material science. Kraig has obtained the exclusive right, in their field of research, for the spider silk gene sequences which are at the core of their technology. These genetic sequences were first studied and subsequently patented by Dr. Lewis of the University of Wyoming. In early 2006, the company obtained certain exclusive rights from the University to utilize the sequences in our field of use. Spider Silk is among the strongest fibers produced in nature with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for high performance polymers.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

SOURCE: Kraig Biocraft Laboratories, Inc.

CONTACT: Kraig Biocraft Laboratories, Inc. Kim K. Thompson, CEO

LANSING, Mich., May 29, 2009 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that it has successfully issued its stock dividend. “The issuance of the dividend has been in the planning for some time and has been an important part of the Company’s plan for returning value to our shareholders. Just as important, we believe that the issuance has laid the groundwork for the Company’s long term future,” said CEO Kim K Thompson. “The input we have received from our shareholders throughout this process has been and continues to be overwhelmingly positive. We are also very excited about the progress in the laboratory and are very hopeful that the scientific team can maintain their tremendous forward momentum through the summer and fall and into 2010.”

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

The Kraig Biocraft Laboratories, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4817

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT:

Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO

(517) 336-0807

LANSING, Mich., May 12, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announce that the scientific team is preparing to significantly ramp up the number of genetic insertions performed in the month of May. The team anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

“We are now entering the next phase in which the team is reallocating recourses to genetic insertion,” said CEO Kim Thompson.

“This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

Every targeted DNA packet insertion has the potential to create a new recombinant fiber with commercial applications.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., May 4, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) is pleased to announce that Dr. Malcolm Fraser, working in cooperation with Dr. Wang, Dr. Sohn and other members of the scientific team have recently succeeded in building eight unique DNA constructs which the team is preparing for genetic insertion over the next several weeks. These genetic insertion packets include several that are specifically targeted for the production of new fusion silk proteins.

“These constructs include a number of new DNA combinations that are truly exciting,” said CEO Kim K. Thompson. “The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.” The genetic constructs are customized packets of DNA which provide genetic instructions for the creation of new polymers and spider silk based proteins.

Over the last year, the University of Notre Dame added of Dr. Wang, Dr. Sohn and other scientists to the research team. “Since that time we have seen a dramatic increase in both the quality and quantity of the work performed,” said Thompson. “We are ready to ramp up our effort to insert as many constructs as possible,” added Dr. Fraser.

Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences. The company plans to tap into the $92 billion market for high performance and technical fibers. In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 27, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) confirms that the record date for the stock dividend is today, April 27, 2009. The press release of April 23^rd contained a typographical error and mistakenly referred to April 27^th as the Ex Date. Stock holders are instructed to disregard the April 27 press release.

The ex date is currently set as May 28, 2009. Please use the following link to see

NASDAQ Group’s posting:

http://www.otcbb.com/asp/dividend.asp?sym_id=KBLB&dDate=4/27/2009&sDateType=Record_date

We can not provide trading advice. Please consult with your broker regarding the stock distribution. Stock holders who sell their stock today or before the ex date may be selling the right to the distribution. Please consult with your broker.

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com

LANSING, Mich., April 15, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) has declared a stock dividend. All shareholders of record as of the close of business on the record date will be issued nine additional shares for each share of common stock held. The record date is April 27, 2009.

“This stock dividend is intended to lay the groundwork for the growth of the Company,” said CEO Kim K. Thompson. “It is part of our ongoing efforts to promote capital investment, broaden ownership, improve trading liquidity, and enhance shareholder value. This action is enabled by the Company’s continued success in the laboratory and is consistent with the Board’s commitment to take actions designed to increase capital investment and create a wider distribution of the Company’s stock.”

The declaration of the stock dividend follows the announcement over the last several months of significant increases in laboratory productivity. The Company believes these dramatic increases in productivity are the direct result of the Company’s successful efforts to recruit highly talented scientists and researchers in 2008. “Ultimate credit for the increased pace of work in the laboratory belongs to Dr. Fraser and the University of Notre Dame research team,” said Kim Thompson.

Kraig is a biotechnology company developing advanced materials and high performance polymers. The Company believes that these materials have the potential to make a significant impact on the $92 billion market for high performance and technical fibers. The Company works in cooperation with leading universities and university researchers, and virtually all of the scientific research is conducted within university laboratories. For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig’s CEO, please visit the Company’s web site: www.KraigLabs.com

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.

CONTACT: Kraig Biocraft Laboratories, Inc.

Kim K. Thompson, CEO

(517) 336-0807

info@KraigLabs.com